STOCKS TELEGRAPH

Tag: NASDAQ: ICU

  • 3 Stocks Traders Are Watching: Nexgel (NXGL), SeaStar Medical (ICU), Cardiol Therapeutics (CRDL)

    3 Stocks Traders Are Watching: Nexgel (NXGL), SeaStar Medical (ICU), Cardiol Therapeutics (CRDL)

    Healthcare equities often trade in cycles that reflect both scientific progress and capital market conditions. Periods of heightened enthusiasm tend to coincide with positive clinical readouts or regulatory breakthroughs, while consolidation phases may occur during interim data gaps. Despite this cyclical nature, long-term interest in innovative therapeutics continues to support sector engagement.

    Nexgel Inc (NXGL)

    Nexgel Inc (NASDAQ: NXGL) flaunted a 3.54% decline to $0.59, as the Stock market unbolted on May 08, 2026. During the day, the stock rose to $0.62 and sank to $0.59. Taking a long-term approach, NXGL posted a 52-week range of $0.56-$2.97.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -77.47%. Meanwhile, its Annual Earnings per share during the time were -77.47%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 197.37%. This publicly-traded company’s shares outstanding now amount to $8.14 million, simultaneously with a float of $6.60 million. The organization now has a market capitalization of $6.78 million.

    SeaStar Medical Holding Corp (ICU)

    Witnessing the stock’s movement on the chart, on May 08, 2026, SeaStar Medical Holding Corp (NASDAQ: ICU) had a quiet start as it plunged -7.61% to $4.49. During the day, the stock rose to $4.93 and sank to $4.35. Taking a long-term approach, ICU posted a 52-week range of $2.07-$13.40.

    The Healthcare sector firm’s twelve-monthly sales growth has been -125.73% for the last half of the decade. Meanwhile, its Annual Earnings per share during the time were -125.73%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 44.54%. This publicly-traded company’s shares outstanding now amount to $3.99 million, simultaneously with a float of $3.89 million. The organization now has a market capitalization of $17.93 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is positioning itself for broader long-term growth through the expansion of its pipeline into larger cardiovascular markets. By developing next-generation therapies targeting inflammation and fibrosis, the company is seeking to build a diversified platform capable of addressing major unmet needs in chronic heart disease.

    Market Momentum

    As of May 8, 2026, CRDL closed at $1.32, up 1.54%, with trading volume of 578,846 shares compared to an average volume of 686,648 shares. The company currently carries a market capitalization of $147.418M and a beta of 0.43, reflecting relatively moderate volatility compared to many clinical-stage biotech peers. Shares remain within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.40 suggests significant upside potential tied to future pipeline progress.

    Pipeline Expansion: CRD-38

    Cardiol is developing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience and expand applicability into broader cardiovascular conditions, including heart failure. The therapy targets inflammation and fibrosis, two major biological drivers associated with worsening cardiac function and disease progression.

    Strategic Opportunity

    The recent publication announcement involving CardiolRx™ Phase II data in the Journal of the American Heart Association may further strengthen confidence in Cardiol’s broader anti-inflammatory platform. Positive validation of its scientific approach could support future development efforts for CRD-38 as the company expands beyond recurrent pericarditis into larger market opportunities.

    Outlook

    As CRD-38 advances toward future clinical development, the asset could emerge as an important secondary value driver for Cardiol. Continued progress across the pipeline may strengthen the company’s long-term growth profile and strategic positioning within cardiovascular biotechnology.

  • Why Is SeaStar Medical (ICU) Stock Soaring?

    Why Is SeaStar Medical (ICU) Stock Soaring?

    The shares of SeaStar Medical Holding Corporation (NASDAQ: ICU) are experiencing a remarkable surge of 43.72% in the present market conditions, currently valued at $0.5993 per share.

    SeaStar’s stock performance has notably positioned it as one of the standout gainers of the week, boasting an impressive ascent of over 220% within the preceding five days.

    However, it’s essential to observe that the stock has suffered a significant devaluation of over 95% during the past year. This notable drop could offer an appealing opportunity for investors interested in adding this stock to their investment portfolios.

    In the current market landscape, ICU’s stock is on the ascent, spurred by a significant regulatory milestone. SeaStar Medical (ICU) recently earned the esteemed Breakthrough

    Device Designation from the U.S. Food and Drug Administration (FDA) for its revolutionary Selective Cytopheretic Device (SCD).

    Tailored for utilization in intensive care units (ICUs), the SCD caters to patients facing acute or chronic systolic heart failure and deteriorating renal function while anticipating a left ventricular assist device (LVAD) implantation.

    This FDA recognition is poised to expedite the SCD’s clinical advancement and regulatory evaluation, a noteworthy acknowledgment, as it’s only the ninth such distinction granted by the FDA’s Center for Biologics Evaluation and Research (CBER) since its establishment in 2015.

    Cardiorenal syndrome, typically occurring in severe heart failure cases, carries a grim prognosis. The SCD, however, has the potential to halt the deteriorating condition, especially the hyperinflammatory state driven by the immune system, offering a glimmer of hope.

    Supported by robust preclinical data and a pioneering human study conducted in collaboration with the University of Michigan, ICU asserts that the SCD represents a transformative approach to addressing hyperinflammation in critically ill chronic heart failure patients.

    Having secured FDA Breakthrough Device Designation for adult Acute Kidney Injury (AKI) previously and now for cardiorenal syndrome, ICU is positioned to expand its application to various medical conditions where hyperinflammation is a key factor.

    Further collaboration with the University of Michigan for a larger clinical study aims to bolster the case for a Premarket Approval (PMA) application to the FDA, cementing ICU’s position as a pioneer in innovative medical solutions.